Sepsia Therapeutics

Sepsia Therapeutics, founded in 2019 and based in Barcelona, is pioneering a non-antibiotic, host-directed strategy to treat sepsis, a condition with high mortality and growing incidence. Its core technology leverages natural human scavenger receptors to neutralize pathogen toxins and modulate the immune response, aiming to bypass antibiotic resistance. The company is advancing a multi-pronged pipeline, including the lead program SIXTIDE, through preclinical and clinical development to address a critical unmet medical need.

Platform based on human scavenger-like receptors (SLRs) that target conserved Pathogen-Associated Molecular Patterns (PAMPs) on bacteria and fungi. Enables development of biologics, CAR-T cell therapies, and hemadsorption devices to combat infection and modulate the dysregulated immune response in sepsis.

The competitive landscape for sepsis is fragmented with many past clinical failures, but few novel, non-antibiotic mechanisms in development. Sepsia's direct competitors may include other companies developing immunomodulatory agents or toxin-adsorbing devices, but its specific scavenger receptor platform appears to be a differentiated approach. It also competes for funding and attention in the broader anti-infective space.